¼¼°èÀÇ °£¾Ï Áø´Ü ½ÃÀå
Liver Cancer Diagnostics
»óǰÄÚµå : 1768729
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 275 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,195,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,585,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ °£¾Ï Áø´Ü ½ÃÀåÀº 2030³â±îÁö 220¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 143¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ °£¾Ï Áø´Ü ½ÃÀåÀº 2024-2030³â¿¡ CAGR 7.4%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 220¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ ÀÓ»ó °Ë»ç´Â CAGR 8.4%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 98¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¿µ»ó Áø´Ü ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 7.5%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 37¾ï ´Þ·¯, Áß±¹Àº CAGR 11.1%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ °£¾Ï Áø´Ü ½ÃÀåÀº 2024³â¿¡ 37¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 53¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 11.1%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 3.9%¿Í 6.9%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 4.7%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ °£¾Ï Áø´Ü ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

°£¾Ï Áø´ÜÀº ¾î¶»°Ô Á¶±â ¹ß°ß ¹× Ä¡·á¸¦ ÁøÇàÇϰí Àִ°¡?

°£¾Ï Áø´ÜÀº ºü¸¥ ¼Óµµ·Î ¹ßÀüÇϰí ÀÖÀ¸¸ç, Ä¡·á ¿É¼ÇÀÌ ´õ È¿°úÀûÀÎ Ãʱ⿡ °£¾ÏÀ» ¹ß°ßÇÒ ¼ö ÀÖ´Â ´É·ÂÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. °£¾Ï Áø´Ü Åø·Î´Â ÃÊÀ½ÆÄ, ÄÄÇ»ÅÍ´ÜÃþÃÔ¿µ(CT), ÀÚ±â°ø¸í¿µ»ó(MRI) µîÀÇ ¿µ»ó Áø´Ü ±â¼ú°ú ¾ËÆÄ žƴܹéÁú(AFP) µîÀÇ ¹ÙÀÌ¿À¸¶Ä¿¸¦ ÃøÁ¤ÇÏ´Â Ç÷¾×°Ë»ç°¡ ÀÖ½À´Ï´Ù. °£¾ÏÀº ÁøÇàµÉ ¶§±îÁö ÀÚ°¢Áõ»óÀÌ °ÅÀÇ ¾øÀÌ Á¶¿ëÈ÷ ÁøÇàµÇ´Â °æ¿ì°¡ ¸¹À¸¹Ç·Î Á¶±â ¹ß°ßÀÌ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. °£¿° °¨¿°, ¾ËÄÚ¿Ã ¼·Ãë, ºñ¾ËÄڿüº Áö¹æ°£Áúȯ(NAFLD) µîÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ Àü ¼¼°è¿¡¼­ °£¾Ï ¹ßº´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÷´Ü Áø´Ü Åø¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

¾î¶² ±â¼ú Çõ½ÅÀÌ °£¾Ï Áø´Ü ½ÃÀåÀ» Çü¼ºÇϰí Àִ°¡?

Áø´Ü ±â¼úÀÇ Çõ½ÅÀº °£¾Ï ¹ß°ßÀÇ »óȲÀ» ¹Ù²Ù°í ÀÖ½À´Ï´Ù. Ç÷¾×³» ¼øÈ¯Á¾¾ç¼¼Æ÷(CTC)¿Í DNA¸¦ ºÐ¼®ÇÏ´Â ºñħ½ÀÀû ±â¼úÀÎ ¾×ü»ý°Ë(Liquid Biopsy)Àº °£¾ÏÀ» °ËÃâÇϰí ÁøÇàÀ» ¸ð´ÏÅ͸µÇÏ´Â À¯¸ÁÇÑ Åø·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. À¯Àüü ÇÁ·ÎÆÄÀϸµ°ú Â÷¼¼´ë ¿°±â¼­¿­ ºÐ¼®(NGS)µµ °£¾Ï Áø´Ü¿¡ ÅëÇÕµÇ¾î ¸ÂÃãÇü Ä¡·á Àü·«ÀÇ ÁöħÀÌ µÇ´Â ƯÁ¤ À¯ÀüÀÚ º¯À̸¦ ½Äº°Çϱâ À§ÇØ °£¾Ï Áø´Ü¿¡ ÅëÇյǰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀΰøÁö´É(AI)°ú ¸Ó½Å·¯´×ÀÇ ¹ßÀüÀº ½ºÄµÀÇ ÇØ¼®À» °­È­ÇÏ°í ±âÁ¸ ¹æ¹ýÀ¸·Î´Â ¹ß°ßÇϱ⠾î·Á¿î Á¶±â Á¾¾çÀ» ½Äº°ÇÔÀ¸·Î½á °£¾Ï ¿µ»ó Áø´ÜÀÇ Á¤È®¼ºÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù.

½ÃÀå ¼¼ºÐÈ­´Â °£¾Ï Áø´ÜÀÇ ¼ºÀåÀ» ¾î¶»°Ô Á¤ÀÇÇϴ°¡?

±â¼ú¿¡´Â ¿µ»ó Áø´Ü, ¾×ü»ý°Ë, ¹ÙÀÌ¿À¸¶Ä¿ °Ë»ç°¡ Æ÷ÇԵǸç, ¿µ»ó Áø´ÜÀº ÀÏ»óÀûÀÎ °ËÁø¿¡ ³Î¸® »ç¿ëµÇ°í ÀÖÀ¸¹Ç·Î °¡Àå Å« ºÎºÐÀ» Â÷ÁöÇÕ´Ï´Ù. ¿ëµµ´Â Á¶±â ¹ß°ß, Áø´Ü ¹× ¸ð´ÏÅ͸µ¿¡ À̸£±â±îÁö ´Ù¾çÇϸç, ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ°¡ Àû½Ã¿¡ °³ÀÔÇÏ¿© »ýÁ¸À²À» ³ôÀ̱â À§ÇØ ³ë·ÂÇÔ¿¡ µû¶ó Á¶±â ¹ß°ßÀÌ Å« ¼ö¿ä¸¦ ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ÃÖÁ¾»ç¿ëÀÚ¿¡´Â º´¿ø, Áø´Ü ½ÇÇè½Ç, ¿¬±¸±â°üÀÌ Æ÷ÇԵǸç, º´¿øÀº °£¾Ï °ËÁø ¹× Ä¡·á °èȹÀÇ ¼ö°¡ ¸¹±â ¶§¹®¿¡ ÁÖ¿ä ºÎ¹®À¸·Î ²ÅÈü´Ï´Ù. Áö¿ªÀûÀ¸·Î´Â Áß±¹, ÀϺ» µîÀÇ ±¹°¡¿¡¼­ °£¾Ï À¯º´·üÀÌ ³ô±â ¶§¹®¿¡ ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡¼­ ½ÃÀåÀÌ ºü¸£°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù.

°£¾Ï Áø´Ü ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

°£¾Ï Áø´Ü ½ÃÀåÀÇ ¼ºÀåÀº °£¾Ï ¹ßº´·ü Áõ°¡, Áø´Ü ±â¼ú ¹ßÀü, Á¶±â ¹ß°ß¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡ µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. ƯÈ÷ °£¿° °¨¿°·üÀÌ ³ôÀº Áö¿ª¿¡¼­´Â Àü ¼¼°è¿¡¼­ °£¾Ï ¹ß»ý·üÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, º¸´Ù Á¤È®Çϰí Á¢±ÙÇϱ⠽¬¿î Áø´Ü ÅøÀÇ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¾×ü»ý°Ë, AI¸¦ Ȱ¿ëÇÑ ¿µ»ó Áø´Ü µîÀÇ ±â¼ú ¹ßÀüÀº Á¶±â ¹ß°ßÀÇ Á¤È®µµ¸¦ ³ôÀ̰í, º¸´Ù °³ÀÎÈ­µÈ Ä¡·á Á¢±Ù¹ýÀ» °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¾Ï °ËÁø ¹× Á¶±â Áø´ÜÀ» Àå·ÁÇÏ´Â Á¤ºÎÀÇ ±¸»óÀº ÷´Ü Áø´Ü ÅøÀÇ Ã¤ÅÃÀ» ÃËÁøÇÏ¿© ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

Áø´Ü ±â¼ú( ÀÓ»ó °Ë»ç, ¿µ»ó Áø´Ü, ³»½Ã°æ°Ë»ç, »ý°Ë, ±âŸ Áø´Ü ±â¼ú), ÃÖÁ¾»ç¿ëÀÚ(º´¿ø¡¤Áø´Ü ¿¬±¸¼Ò, Çмú¡¤¿¬±¸±â°ü, ±âŸ ÃÖÁ¾»ç¿ëÀÚ)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹

AI ÅëÇÕ

°ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇÕ´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM³ª ¾÷°èº° SLM Äõ¸®¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ´ë·® ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Liver Cancer Diagnostics Market to Reach US$22.0 Billion by 2030

The global market for Liver Cancer Diagnostics estimated at US$14.3 Billion in the year 2024, is expected to reach US$22.0 Billion by 2030, growing at a CAGR of 7.4% over the analysis period 2024-2030. Laboratory Tests, one of the segments analyzed in the report, is expected to record a 8.4% CAGR and reach US$9.8 Billion by the end of the analysis period. Growth in the Imaging segment is estimated at 7.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.7 Billion While China is Forecast to Grow at 11.1% CAGR

The Liver Cancer Diagnostics market in the U.S. is estimated at US$3.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$5.3 Billion by the year 2030 trailing a CAGR of 11.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.9% and 6.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.7% CAGR.

Global Liver Cancer Diagnostics Market - Key Trends and Drivers Summarized

How Is Liver Cancer Diagnostics Advancing Early Detection and Treatment?

Liver cancer diagnostics are undergoing rapid advancements, improving the ability to detect liver cancer at earlier stages when treatment options are more effective. Diagnostic tools for liver cancer include imaging techniques such as ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI), as well as blood tests that measure biomarkers like alpha-fetoprotein (AFP). Early detection is crucial in liver cancer, as the disease often progresses silently with few symptoms until it reaches advanced stages. With rising global rates of liver cancer due to factors such as hepatitis infections, alcohol consumption, and non-alcoholic fatty liver disease (NAFLD), the demand for advanced diagnostic tools is growing.

What Technological Innovations Are Shaping the Liver Cancer Diagnostics Market?

Innovations in diagnostic technologies are transforming the landscape of liver cancer detection. Liquid biopsy, a non-invasive technique that analyzes circulating tumor cells (CTCs) and DNA in the blood, is emerging as a promising tool for detecting liver cancer and monitoring its progression. Genomic profiling and next-generation sequencing (NGS) are also being integrated into liver cancer diagnostics to identify specific genetic mutations that can guide personalized treatment strategies. Additionally, advances in artificial intelligence (AI) and machine learning are improving the accuracy of liver cancer imaging by enhancing the interpretation of scans and identifying early-stage tumors that may be difficult to detect through traditional methods.

How Do Market Segments Define the Growth of Liver Cancer Diagnostics?

Technologies include imaging, liquid biopsy, and biomarker testing, with imaging representing the largest segment due to its widespread use in routine screenings. Applications span early detection, diagnosis, and monitoring, with early detection driving significant demand as healthcare providers focus on improving survival rates through timely intervention. End-users include hospitals, diagnostic laboratories, and research institutions, with hospitals being the primary segment due to the high volume of liver cancer screenings and treatment planning. Geographically, the market is expanding rapidly in Asia-Pacific due to the high prevalence of liver cancer in countries such as China and Japan.

What Factors Are Driving the Growth in the Liver Cancer Diagnostics Market?

The growth in the liver cancer diagnostics market is driven by several factors, including the rising incidence of liver cancer, advancements in diagnostic technologies, and increasing awareness of early detection. As liver cancer rates climb globally, particularly in regions with high hepatitis infection rates, the need for more accurate and accessible diagnostic tools is intensifying. Technological advancements, such as liquid biopsy and AI-enhanced imaging, are improving the precision of early detection, enabling more personalized treatment approaches. Furthermore, government initiatives to promote cancer screenings and early diagnosis are encouraging the adoption of advanced diagnostic tools, further boosting market growth.

SCOPE OF STUDY:

The report analyzes the Liver Cancer Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Diagnosis Technique (Laboratory Tests, Imaging, Endoscopy, Biopsy, Other Diagnosis Techniques); End-Use (Hospitals & Diagnostic Laboratories, Academic & Research Institutes, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â